Development of a Novel Antibody-Based Oral Factor VIII Mimetic Drug Candidate (Inno8)

Introduction: Hemophilia A, a debilitating X-linked bleeding disorder, originates from a deficiency in coagulation factor VIII (FVIII). The emergence of FVIII mimetic (F8M) antibody drugs have dramatically changed hemophilia treatments through mimicking the activated FVIII functionality by interacting with factor IX (FIX) and factor X (FX), and stimulating the conversion of FX to activated FX. Here we present the pursuit of a pioneering oral F8M hemophilia drug candidate based on the antibody-scaffold variable heavy domain of heavy chain (VHH).